[go: up one dir, main page]

WO2005112999A3 - Cancer treatment with inhibitors of collagen synthesis - Google Patents

Cancer treatment with inhibitors of collagen synthesis Download PDF

Info

Publication number
WO2005112999A3
WO2005112999A3 PCT/US2005/017732 US2005017732W WO2005112999A3 WO 2005112999 A3 WO2005112999 A3 WO 2005112999A3 US 2005017732 W US2005017732 W US 2005017732W WO 2005112999 A3 WO2005112999 A3 WO 2005112999A3
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
agents
inhibitors
cancer treatment
collagen synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/017732
Other languages
French (fr)
Other versions
WO2005112999A2 (en
Inventor
Paul M Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectramed Inc
Original Assignee
Vectramed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectramed Inc filed Critical Vectramed Inc
Publication of WO2005112999A2 publication Critical patent/WO2005112999A2/en
Anticipated expiration legal-status Critical
Publication of WO2005112999A3 publication Critical patent/WO2005112999A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and methods are provided for the treatment of tumors with a combination of anti-collagen agents and anti-neoplastic agents. In some embodiments one or more of the anti-collagen agents and anti-neoplastic agents may be provided in a biocompatible polymer matrix. The invention also provides prodrugs comprising anti-collagen and anti-tumor agent conjugates. The inventive compositions and methods can be useful in shrinking or reducing tumor size by abrogating drug diffusion barriers that are often the result of collagenous extracellular matrix of solid tumors.
PCT/US2005/017732 2004-05-20 2005-05-20 Cancer treatment with inhibitors of collagen synthesis Ceased WO2005112999A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57261104P 2004-05-20 2004-05-20
US60/572,611 2004-05-20

Publications (2)

Publication Number Publication Date
WO2005112999A2 WO2005112999A2 (en) 2005-12-01
WO2005112999A3 true WO2005112999A3 (en) 2009-05-07

Family

ID=35428859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017732 Ceased WO2005112999A2 (en) 2004-05-20 2005-05-20 Cancer treatment with inhibitors of collagen synthesis

Country Status (1)

Country Link
WO (1) WO2005112999A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670590C (en) 2006-12-01 2018-06-12 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Also Published As

Publication number Publication date
WO2005112999A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2004087075A3 (en) Compositions and methods for treating cancer
LUC00011I1 (en)
WO2007047291A3 (en) Anti-glypican-3 antibody
SI1742644T1 (en) Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
MX361467B (en) Isoindoline compounds for use in the treatment of cancer.
TW200515910A (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer
MX2010009670A (en) Polymer paclitaxel conjugates and methods for treating cancer.
MXPA05013642A (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer.
NO20083287L (en) Drugs for the treatment of tumors, and their use
WO2007050784A3 (en) Fixed ratio drug combination treatments for solid tumors
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
TW200722098A (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in pharmaceutical compositions for treating cancer
WO2005112999A3 (en) Cancer treatment with inhibitors of collagen synthesis
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2008039525A3 (en) Cadherin antagonists in combination with anticancer agents for use in cancer treatment
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
PT1618116E (en) Ruthenium(ii) complexes for the treatment of tumors
AU2003293665A1 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy
WO2005023199A3 (en) Socs-3 promoter methylation in cancer
TW202542201A (en) Anti-psma conjugates and methods of using the same
UA90658C2 (en) Composition of a vegf antagonist and an anti-proliferative agent
HK1123212A (en) Fixed ratio drug combination treatments for solid tumors
CY1117088T1 (en) ISOVINOLINE COMPOUNDS FOR USE IN CANCER TREATMENT

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase